- Home
- FVRR vs SNDX Comparison
FVRR vs SNDX Comparison
Compare FVRR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVRR
- SNDX
- Stock Information
- Founded
- FVRR 2010
- SNDX 2005
- Country
- FVRR Israel
- SNDX United States
- Employees
- FVRR N/A
- SNDX N/A
- Industry
- FVRR Business Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- FVRR Consumer Discretionary
- SNDX Health Care
- Exchange
- FVRR Nasdaq
- SNDX Nasdaq
- Market Cap
- FVRR 1.1B
- SNDX 1.1B
- IPO Year
- FVRR 2019
- SNDX 2016
- Fundamental
- Price
- FVRR $29.04
- SNDX $9.48
- Analyst Decision
- FVRR Buy
- SNDX Strong Buy
- Analyst Count
- FVRR 12
- SNDX 11
- Target Price
- FVRR $35.00
- SNDX $35.91
- AVG Volume (30 Days)
- FVRR 457.9K
- SNDX 1.8M
- Earning Date
- FVRR 07-30-2025
- SNDX 07-31-2025
- Dividend Yield
- FVRR N/A
- SNDX N/A
- EPS Growth
- FVRR 127.71
- SNDX N/A
- EPS
- FVRR 0.49
- SNDX N/A
- Revenue
- FVRR $405,141,000.00
- SNDX $43,722,000.00
- Revenue This Year
- FVRR $13.12
- SNDX $426.77
- Revenue Next Year
- FVRR $8.65
- SNDX $98.31
- P/E Ratio
- FVRR $60.92
- SNDX N/A
- Revenue Growth
- FVRR 10.41
- SNDX N/A
- 52 Week Low
- FVRR $20.78
- SNDX $8.58
- 52 Week High
- FVRR $36.11
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- FVRR 39.40
- SNDX 36.85
- Support Level
- FVRR $28.96
- SNDX $11.00
- Resistance Level
- FVRR $30.18
- SNDX $11.83
- Average True Range (ATR)
- FVRR 1.06
- SNDX 0.58
- MACD
- FVRR -0.60
- SNDX -0.11
- Stochastic Oscillator
- FVRR 9.44
- SNDX 10.31
About FVRR Fiverr International Ltd. no par value
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.